International braz j urol : official journal of the Brazilian Society of Urology · 2027
Robot-Assisted Vesical Mucosal Graft Ureteroplasty for Long Ureteral Strictures: Mid-term Patency and Donor-Site Outcomes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Yiming, Xiao Xingyuan, Zhou Liang, Wang Tianen, Tang Hao, Li Gonghui, Wang Yi, Luo Guangheng, Yang Xiaojian, Yang Kunlin, Li Zhihua, Li Xinfei, Yang Chenglin, Xu Haoxiang, Li Jian, Wang Zhiyong, Yao Bing, Shen Tianyi, Ge Jingping, Xu Feng, Ge Guangju, Zhu Shibin, Wu Haiyang, Yang Chao, Fang Lu, Tang Xiaohu, Zhang Longlong, Fan Xiaozheng, Wang Wei, Wang Kunjie, Li Bing, Li Xuesong
Аннотация
PURPOSE: To evaluate midterm patency, recovery, and donor-site outcomes after robot-assisted vesical mucosal graft (VMG) ureteroplasty for long ureteral strictures.
MATERIALS AND METHODS: This retrospective cohort included 46 VMG procedures and 21 clinically allocated buccal mucosal graft (BMG) reference procedures. The primary outcome was intervention-free patency at last follow-up. Secondary outcomes included workflow, recovery, donor-site morbidity, 30-day complications, hydronephrosis, and renal function. Continuous outcomes were assessed using adjusted models.
RESULTS: Mean follow-up was 41.4 months after VMG and 42.7 months after BMG; intervention-free patency was 93.5% and 90.5%, respectively. All five recurrent obstructions were detected at 3-6 months and required endoscopic reintervention. Hydronephrosis regressed and differential renal function remained stable. Adjusted differences favored VMG for graft preparation, operative time, hospital stay, regular diet, and day 1 harvest-site pain. Differences were -23.1 minutes (95% confidence interval -32.0 to -14.2) for operative time and -1.9 points (-2.4 to -1.4) for pain. Regular diet resumed 2.1 days earlier in the adjusted analysis. Additional donor-site medication was required in 8.7% versus 61.9%; 30-day grade I-II complications occurred in 10.9% versus 61.9%. Four BMG recipients had oral bleeding; paresthesia persisted at 6 months in three. No VMG recipient had urinary leak, impaired bladder healing, or persistent bladder-related functional complaints. No grade ≥III complication occurred within 30 days.
CONCLUSIONS: Robot-assisted VMG ureteroplasty achieved durable midterm drainage and enabled recipient-defect-driven graft sizing within a single operative field. Its broad native urothelial donor surface avoided oral harvest, reduced donor-site burden, and accelerated recovery.
MATERIALS AND METHODS: This retrospective cohort included 46 VMG procedures and 21 clinically allocated buccal mucosal graft (BMG) reference procedures. The primary outcome was intervention-free patency at last follow-up. Secondary outcomes included workflow, recovery, donor-site morbidity, 30-day complications, hydronephrosis, and renal function. Continuous outcomes were assessed using adjusted models.
RESULTS: Mean follow-up was 41.4 months after VMG and 42.7 months after BMG; intervention-free patency was 93.5% and 90.5%, respectively. All five recurrent obstructions were detected at 3-6 months and required endoscopic reintervention. Hydronephrosis regressed and differential renal function remained stable. Adjusted differences favored VMG for graft preparation, operative time, hospital stay, regular diet, and day 1 harvest-site pain. Differences were -23.1 minutes (95% confidence interval -32.0 to -14.2) for operative time and -1.9 points (-2.4 to -1.4) for pain. Regular diet resumed 2.1 days earlier in the adjusted analysis. Additional donor-site medication was required in 8.7% versus 61.9%; 30-day grade I-II complications occurred in 10.9% versus 61.9%. Four BMG recipients had oral bleeding; paresthesia persisted at 6 months in three. No VMG recipient had urinary leak, impaired bladder healing, or persistent bladder-related functional complaints. No grade ≥III complication occurred within 30 days.
CONCLUSIONS: Robot-assisted VMG ureteroplasty achieved durable midterm drainage and enabled recipient-defect-driven graft sizing within a single operative field. Its broad native urothelial donor surface avoided oral harvest, reduced donor-site burden, and accelerated recovery.